Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Avatar

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy

By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Sundar Jagannath
October 24, 2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Scripps MD Anderson Cancer Center

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology 2021

Sat, Feb 20, 2021
The Royal Marsden School

Demystifying the Science Behind Targeted Treatments for Haematological C...

Tue, Feb 2, 2021
Total Health Conferencing

Virtual West Oncology Conference

Fri, Feb 26, 2021
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering MM, I...

Feat. K. Shain
12:44
Bart Barlogie

Clinical Manifestations & Diagnostic Work Up of Myeloma

09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therap...

Feat. A. Rosko
14:16
2nd SOHO Italian Conference

2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do T...

Feat. K. Anderson
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs, mSMART Classi...

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
19:49
Gareth J Morgan

Contemporary Design of MM Treatment: Developing New Therapeutic Endpoint...

17:03
Ajai Chari

Diagnosing Smoldering Multiple Myeloma

09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
05:05
Indy Hematology Review

Risk of Progression of Smoldering Myeloma to Active Multiple Myeloma

Feat. K. Anderson
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial